Aminosalicylic Acid

Brand names: Paser
Drug class: Antineoplastic Agents

Usage of Aminosalicylic Acid

Tuberculosis

Treatment of active (clinical) tuberculosis (TB) in conjunction with other antituberculosis agents. Designated an orphan drug by the US FDA for this use.

Second-line agent used in treatment of drug-resistant TB caused by Mycobacterium tuberculosis known or presumed to be susceptible to aminosalicylic acid.

For initial treatment of active TB caused by drug-susceptible M. tuberculosis, recommended multiple-drug regimens consist of an initial intensive phase (2 months) and a continuation phase (4 or 7 months). Although the usual duration of treatment for drug-susceptible pulmonary and extrapulmonary TB (except disseminated infections and TB meningitis) is 6–9 months, ATS, CDC, and IDSA state that completion of treatment is determined more accurately by the total number of doses and should not be based solely on the duration of therapy. A longer duration of treatment (e.g., 12–24 months) usually is necessary for infections caused by drug-resistant M. tuberculosis.

Patients with treatment failure or drug-resistant M. tuberculosis, including multidrug-resistant (MDR) TB (resistant to both isoniazid and rifampin) or extensively drug-resistant (XDR) TB (resistant to both isoniazid and rifampin and also resistant to a fluoroquinolone and at least one parenteral second-line antimycobacterial such as capreomycin, kanamycin, or amikacin), should be referred to or managed in consultation with experts in the treatment of TB as identified by local or state health departments or CDC.

Ulcerative Colitis and Crohn's Disease

Has been used in the treatment of mild to moderate ulcerative colitis† [off-label] in patients intolerant of sulfasalazine. Also has been used in the treatment of Crohn's disease† [off-label]. Designated an orphan drug by the US FDA for use in these conditions.

Usually, 5-aminosalicylic acid analogs (e.g., balsalazide, mesalamine, olsalazine) are used in the management of ulcerative colitis or Crohn's disease; aminosalicylic acid is a 4-aminosalicyclic acid analog.

Relate drugs

How to use Aminosalicylic Acid

Administration

Oral Administration

Administer orally. Has been administered IV, but a parenteral preparation is not commercially available in the US.

The delayed-release granules (Paser) have an acid-resistant coating designed to protect against degradation in the stomach so that the drug is released gradually and high peak concentrations are avoided.

To protect the acid-resistant coating, administer the granules in food or drink with a pH <5. The granules can be sprinkled on applesauce or yogurt. Alternatively, they can be suspended in a fruit drink (e.g., orange, apple, tomato, grapefruit, grape, or cranberry juices, “fruit punch”); the granules will sink in the juice and must be resuspended by swirling. The granules should be swallowed whole without chewing.

Patients receiving antacids do not need to take the delayed-release granules in an acidic food or drink.

Dosage

Should not be used alone for treatment of active (clinical) TB; must be given in conjunction with other antituberculosis agents.

Data not available to date to support use of aminosalicylic acid in intermittent (e.g., 1–3 times weekly) multiple-drug TB regimens.

Pediatric Patients

Tuberculosis Treatment of Active (Clinical) Tuberculosis Oral

Children <15 years of age or weighing ≤40 kg: 200–300 mg/kg daily (up to 10 g daily) given in 2–4 divided doses recommended by ATS, CDC, IDSA, and AAP.

Adolescents ≥15 years of age: 8–12 g daily given in 2 or 3 divided doses recommended by ATS, CDC, and IDSA.

Adults

Tuberculosis Treatment of Active (Clinical) Tuberculosis Oral

Manufacturer recommends 4 g 3 times daily.

8–12 g daily given in 2 or 3 doses recommended by ATS, CDC, and IDSA. There is some evidence that 4 g twice daily achieves target serum concentrations.

Prescribing Limits

Pediatric Patients

Treatment of Active (Clinical) Tuberculosis Oral

Maximum 10 g daily recommended by ATS, CDC, IDSA, and AAP.

Special Populations

Hepatic Impairment

Dosage adjustment not necessary, but increased clinical and laboratory monitoring recommended. Clearance is not altered in patients with hepatic impairment, but these patients may not tolerate the drug as well as those with normal hepatic function.

Renal Impairment

Contraindicated in severe renal disease (end-stage renal disease).

Some experts recommend 4 g twice daily for treatment of active TB in patients with Clcr <30 mL/minute or undergoing hemodialysis. Doses should be given after hemodialysis since the drug is removed by this procedure; supplemental doses not necessary.

Warnings

Contraindications

  • Hypersensitivity to aminosalicylic acid or any ingredient in the formulation.
  • Severe renal disease (end-stage renal disease).

    • Warnings/Precautions

    Warnings

    Hepatic Effects

    Drug-induced hepatitis reported. Prompt recognition of symptoms and discontinuance of aminosalicylic acid usually results in recovery; failure to recognize the reaction has resulted in fatalities.

    Initial symptoms usually appear within 3 months after the drug is initiated. Rash is the most common symptom; fever and GI disturbances (anorexia, nausea, diarrhea) may occur. Premonitory symptoms usually precede jaundice by several days or weeks (mean time to onset is 33 days; range 7–90 days). Hepatomegaly with lymphadenopathy, leukocytosis, and eosinophilia usually is present when hepatitis is diagnosed.

    Monitor closely during the first 3 months of treatment. Immediately discontinue the drug at the first sign of a rash, fever, or other premonitory signs of intolerance.

    Sensitivity Reactions

    Hypersensitivity Reactions

    Hypersensitivity reactions, including fever, skin eruptions of various types, pruritus, vasculitis, exfoliative dermatitis, joint pain, eosinophilia, leukopenia, agranulocytosis, thrombocytopenia, hepatitis, and jaundice, reported.

    If manifestations of hypersensitivity occur (e.g., rash, fever), immediately discontinue all drugs. After symptoms abate, cautiously reinitiate the drugs one at a time in small and gradually increasing doses to determine whether manifestations were drug-induced and, if so, which drug was responsible.

    Desensitization

    Desensitization has been used when reinitiation of the drug was considered necessary in a patient who had a hypersensitivity reaction.

    One desensitization procedure used successfully in 15 of 17 patients involved an initial 10-mg dose of the drug, doubling dosage every 2 days until a total daily dosage of 1 g was reached, then continuing dosage escalation while giving the total daily dosage in divided doses according to the usual administration schedule (i.e., 3 times daily).

    If mild temperature elevation or skin reaction develops during the desensitization procedure, manufacturer states desensitization may be continued by decreasing the dosage by one increment (i.e., to the previous level at which no reaction occurred) or maintaining current dosage for another 2-day cycle before continuing dosage progression. Such reactions are rare after a total daily aminosalicylic acid dosage of 1.5 g is reached.

    General Precautions

    Precautions Related to Treatment of Tuberculosis

    Should not be used alone for treatment of active (clinical) TB; must be given in conjunction with other antituberculosis agents.

    Clinical specimens for microscopic examination and mycobacterial cultures and in vitro susceptibility testing should be obtained prior to initiation of antituberculosis therapy and periodically during treatment to monitor therapeutic response. The antituberculosis regimen should be modified as needed. Patients with positive cultures after 4 months of treatment should be considered to have failed treatment (usually as the result of noncompliance or drug-resistant TB).

    If added as a new drug to a regimen in patients experiencing treatment failure who have proven or suspected drug-resistant TB, at least 2 (preferably 3) new drugs known or expected to be active against the resistant strain should be added at the same time.

    Compliance with the full course of antituberculosis therapy and all drugs included in the multiple-drug regimen is critical. Missed doses increase the risk of treatment failure and increase the risk that M. tuberculosis will develop resistance to the antituberculosis regimen.

    To ensure compliance, ATS, CDC, IDSA, and AAP recommend that directly observed (supervised) therapy (DOT) be used for treatment of active TB whenever possible, especially when intermittent regimens are used, when the patient is immunocompromised or infected with HIV, or when drug-resistant M. tuberculosis is involved.

    Malabsorption

    Malabsorption of vitamin B12, folic acid, iron, and lipids has occurred, possibly as the result of increased peristalsis. As a result of competition, a 5-g dose of aminosalicylic acid may reduce absorption of vitamin B12 by about 55%; clinically important erythrocyte abnormalities may develop.

    Consider using vitamin B12 maintenance therapy in patients receiving aminosalicylic acid for >1 month.

    Laboratory Monitoring

    Assess hepatic enzyme concentrations and thyroid function prior to initiation of therapy. Assess thyroid function every 3 months.

    Specific Populations

    Pregnancy

    Category C.

    ATS, CDC, and IDSA state that, although aminosalicylic acid has been used safely during pregnancy, the drug should be used in pregnant women only when there are no alternatives for treatment of MDR TB.

    Lactation

    Distributed into milk.

    Hepatic Impairment

    Use with caution. Metabolism of aminosalicylic acid in patients with hepatic disease is comparable to that in healthy individuals, but such patients may tolerate aminosalicylic acid less well. (See Hepatic Effects under Cautions.)

    Renal Impairment

    Use with caution. Contraindicated in patients with severe renal disease (end-stage renal disease).

    Patients with severe renal disease accumulate aminosalicylic acid and its acetyl metabolite but continue to acetylate the drug, resulting exclusively in the inactive acetylated form.

    Common Adverse Effects

    GI effects (nausea, vomiting, abdominal pain, diarrhea).

    What other drugs will affect Aminosalicylic Acid

    Specific Drugs

    Drug

    Interaction

    Comments

    Ammonium chloride

    Increased risk of crystalluria

    Do not use concomitantly

    Anticoagulants, oral

    Enhanced hypoprothrombinemic effect

    Anticoagulant dosage adjustment may be necessary

    Diphenhydramine

    Impaired GI absorption of aminosalicylic acid

    Avoid concurrent use

    Digoxin

    Decreased GI absorption of digoxin

    Isoniazid

    Reduced rate of acetylation of isoniazid (especially in rapid acetylators) reported with some aminosalicylic acid preparations; appears to be dose related

    Interaction not studied using commercially available aminosalicylic acid delayed-release granules (Paser); the lower serum concentrations produced by the delayed-release preparation should result in a reduced effect on acetylation of isoniazid

    Not considered clinically important

    Probenecid

    Conflicting reports, but does not appear to increase plasma concentrations of aminosalicylic acid

    Rifampin

    Decreased serum rifampin concentrations reported with certain aminosalicylic acid preparations; not reported with commercially available aminosalicylic acid delayed-release granules (Paser)

    May be caused by an excipient not included in commercially available aminosalicylic acid delayed-release granules (Paser)

    Vitamin B12

    Decreased oral absorption of vitamin B12; clinically important erythrocyte abnormalities reported

    Consider use of maintenance vitamin B12 treatment in those receiving aminosalicylic acid for >1 month

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords